Friday, March 23, 2018

Dr. Stoxxman Aggressive Venture Portfolio - Update

Patriot One Technologies Inc. - PAT.v aims to directly address the growing Active Threat phenomena which has become a significant force for shaping research in weapons detection. Portable devices and software solutions assist security personnel in the detection of concealed weapons. $ 1.94
PAT closed a big financing.
PyroGenesis Canada Inc. - PYR.v is a leader in the design, development, manufacture and commercialization of advanced plasma processes. $ .68
PYR closed a big financing.
Orca Gold Inc. - ORG.v is an exploration company focused in North and West Africa. Orca's flagship project is the Block 14 gold project, located in northern Sudan, near the border with Egypt. $ .53
Red Back boys are drilling in Sudan.
Pascal Biosciences Inc. - PAS.v was founded in 2013 in Vancouver, based on discovery research at UBC. Pascal is a biotechnology company focused on harnessing the body’s immune system to fight cancer. Mission is to discover and develop innovative therapeutics that empower the immune system to help patients suffering from life-threatening diseases. Last at $ .48
Tightly held in the Cannabis space.
Canada Jetlines Ltd. - JET.v is set to become Canada’s first ultra-low fare airline. Jetlines was created to serve the millions of Canadians living in unserved or underserved markets across the country. $ 1.13
Co's deal for leased aircaft falls flat, launch delayed.
Additions ...
Cornerstone Metals Inc. - CCC.v is advancing the flagship Carlin Vanadium Project. The Carlin Vanadium Project contains one of North America’s largest, richest known primary deposits of vanadium. Cornerstone also owns 100% of the West Jerome property, near Jerome, Arizona​. $ .41
Co is moneyed up and vanadium is hot.
Antibe Therapeutics Inc. - ATE.v develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. $ .48
Co's main drug passes trials.